

POSTER PRESENTATION

Open Access

Response to growth hormone therapy in children with Noonan syndrome: correlation with or without *PTPN11* Gene mutation

Yoo-Mi Kim^{1*}, Jin-Ho Choi¹, Beom Hee Lee¹, Chang-Woo Jung¹, Hye Young Jin¹, Jae-Min Kim², Gu-Hwan Kim², Jin Soon Hwang³, Sei Won Yang⁴, Jin Lee¹, Han-Wook Yoo¹

From 7th APPES Biennial Scientific Meeting
Nusa Dua, Bali. 14-17 November 2012

Aims

Noonan syndrome (NS) (MIM 163950) is an autosomal dominant disorder characterized by postnatal short stature, congenital heart disease, early feeding difficulties, mild learning disabilities, and characteristic facial dysmorphisms, short and webbed neck, and chest deformities. Proportionate short stature is well recognized as one of the key features of NS and has been reported in more than 80% of patients affected by NS. The objective of this study was to evaluate the efficacy of recombinant human growth hormone (rhGH) therapy and the influence of genotype on the response to rhGH therapy in children with Noonan syndrome (NS).

Methods

Fourteen male and four female subjects with NS with short stature whose height was less than third percentile, were included. The rhGH was subcutaneously administered at a dose of 66 µg/kg/day, subcutaneously for a 12-month period. Mutations in the *PTPN11* gene were identified in 10 subjects (55.6%). Mutations in the *SOS1* (two children, 11.1%), *MEK1* (one child, 5.6%) and *KRAS* (one child, 5.6%) genes were also found.

Results

The mean age was 8.3 ± 2.4 years (range, 4.4 to 13.2 years) at the start of rhGH treatment. Height-SDS increased from -2.8 ± 0.9 at the start of rhGH therapy to -2.0 ± 0.9 12 months later ($P < 0.001$). Height velocity increased from 5.0 ± 0.9 cm/year in the year before treatment to 8.9 ± 1.6 during treatment ($P < 0.001$). Changes in height SDS,

height velocity, and serum IGF-1 level did not differ significantly between those children with or without *PTPN11* mutations.

Conclusion

The rhGH therapy significantly improved the growth velocity and increased the serum IGF-1 level. Long-term correlation between genotype and rhGH therapy responsiveness needs to be addressed in a large population.

Authors' details

¹Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. ²Medical Genetics Center, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea. ³Department of Pediatrics, Ajou University School of Medicine, Ajou University Hospital, Suwon, Korea. ⁴Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea.

Published: 3 October 2013

doi:10.1186/1687-9856-2013-S1-P51

Cite this article as: Kim et al.: Response to growth hormone therapy in children with Noonan syndrome: correlation with or without *PTPN11* Gene mutation. *International Journal of Pediatric Endocrinology* 2013 **2013**(Suppl 1):P51.

¹Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Korea
Full list of author information is available at the end of the article